Wang Lin, Li Penghui, Feng Kun
Pingshan District People's Hospital of Shenzhen, Pingshan General Hospital of Southern Medical University, Shenzhen, 518118, Guangdong, China.
Center for Health Research, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, Guangdong, China; University of Chinese Academy of Sciences, Beijing, 100049, China.
Eur J Med Chem. 2023 Mar 15;250:115197. doi: 10.1016/j.ejmech.2023.115197. Epub 2023 Feb 10.
The resistance of cancer cells to chemotherapeutic drugs greatly reduces the therapeutic effect in cancer patients, and the toxic side effects caused by chemotherapy also seriously affect the quality of life of patients. The combination of epigallocatechin-3-gallate (EGCG), the main active ingredient in tea, with cisplatin, 5-FU, doxorubicin and paclitaxel enhances their sensitizing effect on tumors and combats the drug resistance of cancer cells. These effects seem to be mediated by a variety of mechanisms, including combating drug resistance mediated by cancer stem cells, enhancing drug sensitivity, inducing cell cycle arrest and apoptosis, and blocking angiogenesis. In addition, EGCG can suppress a series of adverse effects caused by chemotherapy, such as gastrointestinal disorders, nephrotoxicity and cardiotoxicity, through its anti-inflammatory and antioxidant effects and improve the quality of life of patients. However, the low bioavailability and off-target effects of EGCG and its reactivity with some chemotherapeutic agents limit its clinical application. The nanomodification of EGCG and chemotherapeutic drugs not only enhances the antitumor activity but also prolongs the survival time of tumor-bearing mice, and has the advantage of low toxicity. Therefore, this review aims to discuss the current status and challenges regarding the use of EGCG in combination with chemotherapy drugs in the treatment of cancer. In general, EGCG is a promising adjuvant for chemotherapy.
癌细胞对化疗药物的耐药性大大降低了癌症患者的治疗效果，而且化疗引起的毒副作用也严重影响患者的生活质量。表没食子儿没食子酸酯（EGCG）是茶叶中的主要活性成分，它与顺铂、5-氟尿嘧啶、阿霉素和紫杉醇联合使用可增强它们对肿瘤的增敏作用，并对抗癌细胞的耐药性。这些作用似乎是由多种机制介导的，包括对抗癌症干细胞介导的耐药性、增强药物敏感性、诱导细胞周期停滞和凋亡以及阻断血管生成。此外，EGCG可通过其抗炎和抗氧化作用抑制化疗引起的一系列不良反应，如胃肠道紊乱、肾毒性和心脏毒性，并改善患者的生活质量。然而，EGCG的低生物利用度、脱靶效应及其与某些化疗药物的反应性限制了其临床应用。对EGCG和化疗药物进行纳米改性不仅能增强抗肿瘤活性，还能延长荷瘤小鼠的生存时间，且具有低毒性的优势。因此，本综述旨在讨论EGCG与化疗药物联合用于癌症治疗的现状和挑战。总的来说，EGCG是一种很有前景的化疗辅助药物。
